CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

CADTH Provisional Funding Algorithms Offer Additional Support for the Implementation of Oncology Drug Reimbursement Recommendations

February 26, 2021
On February 25, CADTH issued our first provisional funding algorithm — a form of expert advice that supports provincial and territorial drug programs and cancer agencies in implementing our cancer drug reimbursement recommendations. CADTH can issue a provisional funding algorithm when a new recommendation in favour of reimbursement may impact t...

Suzanne McGurn Discusses Keeping Evidence Current in New NPC Podcast Episode

February 19, 2021
Suzanne McGurn, President and CEO of CADTH, is the featured guest on a new episode of The NPC Podcast (S03, E03). She talks with host Peter Brenders — CEO of the New Brunswick Health Research Foundation — about taking the reins at CADTH, how the pandemic has affected CADTH’s work, and the evolving evidence landscape.   The NPC Podcast is ...

CADTH Watch List: Artificial intelligence, connected devices, and COVID-19 home sampling among health technology trends gaining momentum in 2021

February 18, 2021
New horizon scan report offers patients, providers, and decision-makers insight on key health technologies that could transform the delivery of care OTTAWA, ON, February 17, 2021 — A new Watch List from CADTH identifies 10 emerging health technology trends that are poised to have a significant influence on the future of health care in Canada. ...

Consultations Help Shape Updated Patient Input Guide

December 3, 2020
Feedback from more than 35 patient groups has helped CADTH update its Guidance for Providing Patient Input — a key resource for patient groups, patients, and caregivers who contribute to our reimbursement review process. The guide now addresses some of the key improvements suggested by patient groups, which include: expanding the definition ...

CADTH Recommends First Gene Therapy Treatment for Rare Form of Childhood Vision Loss

November 26, 2020
Voretigene neparvovec (Luxturna) is the first gene therapy evaluated through the CADTH reimbursement review process CADTH recommends reimbursement with conditions, including a price reduction, and offers advice on implementing the recommendation On November 16, CADTH recommended that Canada’s federal, provincial, and territorial drug pla...